SCHEMBL3689498

SCHEMBL3689498

CC(C)(C)OC(=O)C[C@H](CO)NC(=O)OC(C)(C)C

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.55
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
CA7 P43166 1/20 0.45
CTSK P43235 9/20 0.43
ATM Q13315 1/20 0.40
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
HTT P42858 1/20 0.39
CTSS P25774 5/20 0.39
TDP1 Q9NUW8 1/20 0.39
CTSL P07711 1/20 0.37
CTSB P07858 1/20 0.37
MEN1 O00255 1/20 0.37
GAA P10253 1/20 0.37
KMT2A Q03164 1/20 0.37
HDAC3 O15379 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC2 Q92769 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL344731 1.00 CYP2D6 (0.55) CYP2D6CA1CA2CA7CTSK
SCHEMBL168389 1.00 CYP2D6 (0.55) CYP2D6CA1CA2CA7CTSK
SCHEMBL29990821 1.00 CYP2D6 (0.55) CYP2D6CA1CA2CA7CTSK
SCHEMBL4747461 0.97 CYP2D6 (0.53) CYP2D6CA1CA2CA7CTSK
SCHEMBL14489658 0.91 CYP2D6 (0.46) CYP2D6CA1CA2CA7CTSK
SCHEMBL272147 0.91 CYP2D6 (0.46) CYP2D6CA1CA2CA7CTSK
SCHEMBL272149 0.91 CYP2D6 (0.46) CYP2D6CA1CA2CA7CTSK
SCHEMBL3414965 0.87 CYP1A2 (0.51) CYP2D6CA1CA2CA7CTSK
SCHEMBL1968178 0.87 CYP2D6 (0.47) CYP2D6CA1CA2CA7CTSK
SCHEMBL1968182 0.87 CYP2D6 (0.47) CYP2D6CA1CA2CA7CTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025021833-A1 MULTIVALENT CARGO-CARRYING COMPLEXES AND USES THEREOF ASTRAZENECA AB (SE) 2025-01-30 WO disclosed
CN-108026026-B Beta-substituted beta-amino acids and analogs as chemotherapeutic agents and uses thereof 夸德里加生物科学公司 2021-02-09 CN disclosed
EP-3083564-B1 HETEROARYL BUTANOIC ACID DERIVATIVES AS LTA4H INHIBITORS NOVARTIS AG (CH) 2018-07-11 EP disclosed
US-20180170887-A1 NOVEL HETEROARYL BUTANOIC ACID DERIVATIVES NOVARTIS PHARMA AG (CH) 2018-06-21 US disclosed
US-9981926-B2 Heteroaryl butanoic acid derivatives NOVARTIS AG (CH) 2018-05-29 US disclosed
US-20170015637-A1 NOVEL HETEROARYL BUTANOIC ACID DERIVATIVES NOVARTIS AG (CH) 2017-01-19 US disclosed
US-8410150-B2 Inhibitors of carnitine palmitoyltransferase and treating cancer UNIVERSITY HEALTH NETWORK (CA) 2013-04-02 US disclosed
US-20100105900-A1 INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER UNIVERSITY HEALTH NETWORK 2010-04-29 US disclosed
WO-2008109991-A1 INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER UNIVERSITY HEALTH NETWORK (CA) 2008-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180170887-A1 NOVEL HETEROARYL BUTANOIC ACID DERIVATIVES LTA4H, LTC4S, LTB4R CYP2D6 166/4885CA1 4679/4885CA2 4057/4885
US-20100105900-A1 INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER CPT1A, CPT1B, CPT2 CYP2D6 1791/4885CA1 1983/4885CA2 1295/4885
US-20170015637-A1 NOVEL HETEROARYL BUTANOIC ACID DERIVATIVES LTA4H, LTC4S, LTB4R CYP2D6 166/4885CA1 4679/4885CA2 4057/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.